Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back

25

United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout.

Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.)

UTHR paused for about three weeks and pulled back toward $215. That level is …

For more, please click here to view the related idea and chart analysis on TradingView.

United Therapeutics (UTHR), daily chart with selected patterns and indicators, courtesy of TradingView.
Advertisement Trading Platforms and Tools